Search

The process of medical innovation – evolving trends and future perspectives

In 2018 the United Kingdom Government spending on healthcare totalled almost £166 billion. Of this approximately 65% was attributed to providing curative or rehabilitation therapy, with health-related long-term care and provision of goods accounting for 25%. The remaining was accredited...

Scalpels and stunts: reflections from an academic trainee and international-level athlete

When people find out I’m a urology registrar, they usually nod politely or giggle for obvious reasons. When they find out I’m also a competitive cheerleader, they tend to blink, pause, and then ask: “Wait, like pom-poms and high kicks?”...

RSM Paediatric Urology Meeting and Presidential Address 2023

The academic year of the Urological Section of the Royal Society of Medicine (RSM) started with a bang in October last year with the Paediatric Urology meeting, co-organised by Shabnam Undre (Paediatric Representative for BAUS and Consultant Paediatric Urologist East...

Sexual dysfunction following prostate cancer treatment

Prostate cancer is common with over 52,300 new cases diagnosed annually in the UK; this is expected to rise by 15% between 2023-2025 and 2038-2040 [1]. Radical prostatectomy continues to be the most common form of radical treatment for men...

Redundant! Do urological surgeons have a future in treating urological cancers? RSM Urology Section Meeting

December 2023 marked the latest RSM Urology Section event. Alongside the Winter Short Papers Prize presentations, the theme of the day was major urological cancers and the role of the urologist in patient management within the multidisciplinary team (MDT). We...

Obesity and Urologic cancers: A student’s perspective on risk, systems and surgical implications

During my clinical placements, I began to notice that some patients did not fit neatly into the scenarios we learned about in lectures. One patient in particular had a raised PSA and several comorbidities, including obesity. What stood out was...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Small renal masses – diagnosis and management

Renal cancer is the eighth most common cancer in the UK and accounts for about 3% of all new cancer diagnoses [1]. The incidence rates are steadily rising, with the highest rates being in older men and women. This rise...